EP2056830A4 - Compositions useful especially for treatment or prevention of metabolic syndrome - Google Patents
Compositions useful especially for treatment or prevention of metabolic syndromeInfo
- Publication number
- EP2056830A4 EP2056830A4 EP07803696A EP07803696A EP2056830A4 EP 2056830 A4 EP2056830 A4 EP 2056830A4 EP 07803696 A EP07803696 A EP 07803696A EP 07803696 A EP07803696 A EP 07803696A EP 2056830 A4 EP2056830 A4 EP 2056830A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- prevention
- treatment
- metabolic syndrome
- compositions useful
- useful especially
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000001145 Metabolic Syndrome Diseases 0.000 title 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Polymers & Plastics (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI20060768A FI20060768A0 (en) | 2006-08-28 | 2006-08-28 | Compositions especially suitable for treating or preventing metabolic syndrome |
| PCT/FI2007/000206 WO2008025870A1 (en) | 2006-08-28 | 2007-08-22 | Compositions useful especially for treatment or prevention of metabolic syndrome |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP2056830A1 EP2056830A1 (en) | 2009-05-13 |
| EP2056830A4 true EP2056830A4 (en) | 2011-01-12 |
Family
ID=36950669
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP07803696A Withdrawn EP2056830A4 (en) | 2006-08-28 | 2007-08-22 | Compositions useful especially for treatment or prevention of metabolic syndrome |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP2056830A4 (en) |
| FI (1) | FI20060768A0 (en) |
| WO (1) | WO2008025870A1 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009023207A1 (en) * | 2007-08-13 | 2009-02-19 | Synvista Therapeutics, Inc. | Thiazolium compounds for treating gastrointestinal complications |
| WO2009051804A1 (en) * | 2007-10-18 | 2009-04-23 | Synvista Therapeutics, Inc. | Thiazolium compounds for treating or preventing diseases associated with insulin resistance |
| US8906642B2 (en) | 2008-09-03 | 2014-12-09 | Universitat Autonoma De Barcelona | Methods and compositions for the treatment and diagnosis of haemorrhagic conversion |
| AU2014279863A1 (en) | 2013-06-12 | 2016-01-28 | Proximagen Limited | New therapeutic uses of enzyme inhibitors |
| WO2015189534A1 (en) | 2014-06-12 | 2015-12-17 | Proximagen Limited | Vap-1 inhibitors for treating muscular dystrophy |
| AU2016366635A1 (en) | 2015-12-07 | 2018-06-21 | Benevolentai Cambridge Limited | VAP-1 inhibitors for treating pain |
| US20220354847A1 (en) * | 2019-09-26 | 2022-11-10 | The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization | Thiamine therapy for fatty liver associated diseases |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4558050A (en) * | 1984-03-01 | 1985-12-10 | University Of Florida | Treatment of metabolic disorders with dichloroacetate-thiamine preparations |
| CA2066951A1 (en) * | 1991-04-26 | 1992-10-27 | Kou Moriyama | Edible composition |
| CN1142778C (en) * | 1995-01-18 | 2004-03-24 | 奥尔顿有限公司 | Use of thiazolium compounds for preventing and reversing the formation of advanced glycation end products |
| DE19629803A1 (en) * | 1996-07-24 | 1998-01-29 | Woerwag Pharma Gmbh | Medicines used to treat neuropathies |
| DE19629802A1 (en) * | 1996-07-24 | 1998-01-29 | Woerwag Pharma Gmbh | Medicines used to treat neuropathies |
| DE10353535A1 (en) * | 2003-11-14 | 2005-06-16 | Bayer Healthcare Ag | Combination comprises benfotiamine, a chromium salt and folic acid, useful e.g. for improving impaired metabolism, especially in diabetics |
| PL1708711T3 (en) * | 2004-01-30 | 2010-10-29 | Biotie Therapies Oyj | Compositions useful especially for treatment or prevention of metabolic syndrome |
| US20090209554A1 (en) * | 2004-03-24 | 2009-08-20 | Array Biopharma Inc. | Thiazoliums as transketolase inhibitors |
| JP2006008576A (en) * | 2004-06-25 | 2006-01-12 | Kosei Tanaka | Inhibitor against activation of hexamine biosynthesis pathway |
| US20060089316A1 (en) * | 2004-10-25 | 2006-04-27 | Brown Truman R | Method for reducing a susceptibility to tumor formation induced by 3-deoxyglucosone and precursors thereof |
-
2006
- 2006-08-28 FI FI20060768A patent/FI20060768A0/en not_active Application Discontinuation
-
2007
- 2007-08-22 WO PCT/FI2007/000206 patent/WO2008025870A1/en not_active Ceased
- 2007-08-22 EP EP07803696A patent/EP2056830A4/en not_active Withdrawn
Non-Patent Citations (2)
| Title |
|---|
| No further relevant documents disclosed * |
| See also references of WO2008025870A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008025870A1 (en) | 2008-03-06 |
| FI20060768A0 (en) | 2006-08-28 |
| EP2056830A1 (en) | 2009-05-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI2079760T1 (en) | Compositions and methods for the treatment of infections | |
| ZA200902374B (en) | Compositions useful for the treatment of diabetes | |
| EP1871331A4 (en) | Composition for treatment of menopause | |
| IL199903A0 (en) | Compositions comprising a synergistic combination of agents for treating metabolic syndrome | |
| IL187999A0 (en) | Compositions for the treatment of persistent infections | |
| IL196465A0 (en) | Compositions and methods for the treatment of mucositis | |
| IL210997A0 (en) | Compositions for the treatment of mrsa and uses thereof | |
| IL187565A0 (en) | Compositions and methods for the treatment or prevention of chemoresistant neoplasia | |
| IL243294A0 (en) | Compounds and compositions for treatment of cancer | |
| EP2056830A4 (en) | Compositions useful especially for treatment or prevention of metabolic syndrome | |
| GB0909297D0 (en) | Composition for the treatment of skin conditions | |
| IL196901A0 (en) | Compositions for the treatment of chronic degenerative inflammatory conditions | |
| HRP20130791T1 (en) | Pharmaceutical compositions for the treatment of capillary arteriopathy | |
| PL2111855T3 (en) | Antibacterial compositions for the treatment of infections of the upper and lower airways | |
| EP2174956A4 (en) | Compositions for anti-fibrinolitic treatment | |
| IL182055A0 (en) | Agent for prophylaxis or treatment of metabolic syndrome | |
| GB0917745D0 (en) | Compositions for the prevention or treatment of migraine | |
| PL2252302T3 (en) | Composition for the treatment of osteoarthritis | |
| GB0612273D0 (en) | Prevention of muscle atrophy | |
| IL200192A0 (en) | Composition useful for the treatment of type 2 diabetes | |
| HU0500947D0 (en) | Composition for treatment of paradontosis | |
| PL1996207T3 (en) | Compositions comprising chitosan suitable for comprehensive therapeutic treatment or comprehensive prevention of the metabolic syndrome | |
| IL193686A0 (en) | Agent for prevention/treatment of irritable bowel syndrome | |
| GB0808326D0 (en) | Compositions and methods for the treatment of fybromyalgia | |
| GB0808730D0 (en) | Compositions and methods for the prevention and treatment of schistosomiasis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20090130 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR |
|
| AX | Request for extension of the european patent |
Extension state: AL BA HR MK RS |
|
| RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: BIOTIE THERAPIES OYJ |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20101213 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 31/426 20060101ALI20101207BHEP Ipc: A61P 9/10 20060101ALI20101207BHEP Ipc: A61P 3/00 20060101ALI20101207BHEP Ipc: C07D 277/24 20060101ALI20101207BHEP Ipc: A23L 1/302 20060101ALI20101207BHEP Ipc: A61K 31/675 20060101ALI20101207BHEP Ipc: A61K 31/51 20060101AFI20080409BHEP |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20110612 |